Association of apolipoprotein B and incidence of metabolic syndrome in Korean men: A 5-years' follow-up study

Atherosclerosis

Volumn 226, Issue 2, 2013, Pages 496-501

  Ryoo, Jae Hong ^a   Park, Sung Keun ^b  

^a Kyung Hee University Hospital   (South Korea)

^b Sungkyunkwan University   (South Korea)

Author keywords

Apolipoprotein B; Metabolic syndrome

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL;

ADULT; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; FOLLOW UP; HAZARD RATIO; HUMAN; KOREA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MORBIDITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY;

ADULT; APOLIPOPROTEINS B; ASIAN CONTINENTAL ANCESTRY GROUP; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REPUBLIC OF KOREA; RISK FACTORS;

EID: 84872370502     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.11.024     Document Type: Article

References (30)

1. Gami A.S., Witt B.J., Howard D.E., et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007, 49:403-414.
2. Isomaa B., Almgren P., Tuomi T., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683-689.
3. Klein B.E., Klein R., Lee K.E. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in beaver dam. Diabetes Care 2002, 25:1790-1794.
4. Walldius G., Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy-a review of the evidence. J Intern Med 2006, 259:493-519.
5. Olofsson S.O., Wiklund O., Boren J. Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease. Vasc Health Risk Manag 2007, 3:491-502.
6. Lamarche B., Despres J.P., Moorjani S., Cantin B., Dagenais G.R., Lupien P.J. Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Quebec Cardiovascular Study). Am J Cardiol 1995, 75:1189-1195.
7. Lamarche B., Moorjani S., Lupien P.J., et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec Cardiovascular Study. Circulation 1996, 94:273-278.
8. Enkhmaa B., Anuurad E., Zhang Z., Pearson T.A., Berglund L. Usefulness of apolipoprotein B/apolipoprotein A-I ratio to predict coronary artery disease independent of the metabolic syndrome in African Americans. Am J Cardiol 2010, 106:1264-1269.
9. van Lennep J.E., Westerveld H.T., van Lennep H.W., Zwinderman A.H., Erkelens D.W., van der Wall E.E. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Arterioscler Thromb Vasc Biol 2000, 20:2408-2413.
10. Sasongko M.B., Wong T.Y., Nguyen T.T., et al. Serum apolipoprotein AI and B are stronger biomarkers of diabetic retinopathy than traditional lipids. Diabetes Care. 2011, 34:474-479.
11. Seo M.H., Bae J.C., Park S.E., et al. Association of lipid and lipoprotein profiles with future development of type 2 diabetes in nondiabetic Korean subjects: a 4-year retrospective, longitudinal study. J Clin Endocrinol Metab 2011, 96:E2050-E2054.
12. Han J.H., Park H.S., Kim J.A., Kim S.M. Apolipoprotein B is a better marker than non-HDL-cholesterol for the metabolic syndrome in Koreans. Atherosclerosis 2008, 197:333-338.
13. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
14. Alberti K.G., Eckel R.H., Grundy S.M., et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120(16):1640-1645. International Diabetes Federation Task Force on Epidemiology and Prevention, National Heart, Lung, and Blood InstituteNational Heart, Lung, and Blood Institute, American Heart AssociationAmerican Heart Association, World Heart Federation; International Atherosclerosis SocietyWorld Heart Federation; International Atherosclerosis Society, International Association for the Study of ObesityInternational Association for the Study of Obesity.
15. Wen C.P., David Cheng T.Y., Tsai S.P., et al. Are Asians at greater mortality risks for being overweight than Caucasians? Redefining obesity for Asians. Public Health Nutr 2009, 12:497-506.
16. Hanley J.A., McNeil B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982, 143:29-36.
17. Pencina M.J., D'Agostino R.B. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 2004, 23:2109-2123.
18. Harrell F.E., Lee K.L., Mark D.B. Multivariable prognosis model: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996, 15:361-387.
19. Sattar N., Williams K., Sniderman A.D., D'Agostino R., Haffner S.M. Comparison of the associations of apoB and non-HDL cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Study (IRAS). Circulation 2004, 110:2687-2693.
20. Faraj M., Messier L., Bastard J.P., et al. Apolipoprotein B: a predictor of inflammatory status in postmenopausal overweight and obese women. Diabetologia 2006, 49:1637-1646.
21. Schmidt M.I., Duncan B.B., Scharrett A.R., et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999, 353:1649-1652.
22. Duncan B.B., Schmidt M.I., Pankow J.S., et al. Low-grade systemic inflammation and the development of type 2 diabetes: the Atherosclerosis Risk in Communities study. Diabetes 2003, 52:1799-1805.
23. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 1993, 259:87-91.
24. Skålén K., Gustafsson M., Rydberg E.K., et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002, 417:750-754.
25. Onat A., Can G., Hergenç G., Yazici M., Karabulut A., Albayrak S. Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension and diabetes, independent of markers of central obesity and inflammation. Int J Obes 2007, 31:1119-1125.
26. Marcovina S.M., Albers J.J., Kennedy H., Mei J.V., Henderson L.O., Hannon W.H. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material. Clin Chem 1994, 40:586-592.
27. Miremadi S., Sniderman A., Frohlich J. Can measurement of serum apolipoprotein B replace the lipid profile monitoring of patients with lipoprotein disorders?. Clin Chem 2002, 48:484-488.
28. Stevens J., Couper D., Pankow J., et al. Sensitivity and specificity of anthropometrics for the prediction of diabetes in a biracial cohort. Obes Res 2001, 9:696-705.
29. Han T.S., Williams K., Sattar N., Hunt K.J., Lean M.E., Haffner S.M. Prospective analysis of obesity, body fat distribution and hyperinsulinaemia in the development of metabolic syndrome in the San Antonio Heart Study. Obes Res 2002, 10(9):923-931.
30. Nakanishi N., Suzuki K., Tatara K. Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care 2004, 27:1427-1430.